Information Provided By:
Fly News Breaks for April 12, 2017
TEVA, ALDR
Apr 12, 2017 | 07:07 EDT
After spending time with an intellectual property expert, Jefferies analyst Brian Abrahams believes IP concerns relating to Alder Biopharmaceuticals (ALDR) remain overdone. He does not believe Teva's (TEVA) patents will be upheld as valid in the U.S. Abrahams does not think IP conflicts would dissuade potential partners and/or acquirers and keeps a Buy rating on Alder with a $43 price target. The analyst sees a buying opportunity at current levels into the Phase III data.
News For ALDR;TEVA From the Last 2 Days
There are no results for your query ALDR;TEVA